

Amendments to the Claims:


This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-26 (Cancelled)


27 (New). A cell activator comprising a glycosphingolipid having a structure represented by the following formula (1)

formula (1)



wherein R<sup>1</sup> represents the following formula (1-1):

formula (1-1)




wherein R<sup>3</sup> represents alkyl or alkenyl and R<sup>4</sup> represents alkyl; and

$R^2$  represents hydrogen, or  $\alpha$ -galactose,  $\alpha$ -glucose,  $\alpha$ -mannose,  $\alpha$ -glucosamine,  $\beta$ -glucosamine or a combination thereof.


28 (New). A cell activator comprising a glycosphingolipid having a structure represented by the following formula (3):

formula (3)




wherein  $R^5$  represents  $R^{51}$ ,  $R^{52}$ ,  $R^{53}$ ,  $R^{54}$ ,  $R^{55}$ ,  $R^{56}$ ,  $R^{57}$ ,  $R^{58}$ ,  $R^{59}$ ,  $R^{70}$ ,  $R^{71}$ ,  $R^{72}$ ,  $R^{73}$ ,  $R^{74}$ ,  $R^{75}$ ,  $R^{76}$ ,  $R^{77}$ , or  $R^{78}$ ; and  $R^6$  represents hydrogen,  $R^{62}$ ,  $R^{63}$ ,  $R^{64}$ , or  $R^{65}$ :


$R^{51}$  :




$R^{52}$  :




$R^{53}$  :




R<sup>54</sup> :




R<sup>55</sup> :




R<sup>56</sup> :




R<sup>57</sup> :




R<sup>58</sup> :




R<sup>59</sup> :




R<sup>70</sup> :




R<sup>71</sup> :




R<sup>72</sup> :




R<sup>73</sup> :




R<sup>74</sup> :




R<sup>75</sup> :




R<sup>76</sup>:




R<sup>77</sup>:




R<sup>78</sup>:




R<sup>62</sup>:




R<sup>64</sup>:



R<sup>63</sup>:



R<sup>65</sup>:



29 (New). A method of activating NKT cell which comprises administering the cell activator according to claim 27 to a mammal.

30 (New). A method of activating NKT cell which comprises administering the cell activator according to claim 28 to a mammal,

31 (New). A method of accelerating IL-4 production which comprises administering the cell activator according to claim 27 to a mammal.

32 (New). A method of accelerating IL-4 production which comprises administering the cell activator according to claim 28 to a mammal.

33 (New). A method of accelerating IFN- $\gamma$  production which comprises administering the cell activator according to claim 27 to a mammal.

34 (New). A method of accelerating IFN- $\gamma$  production which comprises administering the cell activator according to claim 28 to a mammal.

35 (New). A method of activating dendritic cell which comprises administering the cell activator according to claim 27 to a mammal.

36 (New). A method of activating dendritic cell which comprises administering the cell activator to claim 28 to a mammal.

37 (New). A method of accelerating IL-12 production which comprises administering the cell activator according to claim 27 to a mammal.

38 (New). A method of accelerating IL-12 production which comprises administering the cell activator according to claim 28 to a mammal.

39 (New). A method of accelerating IL-10 production which comprises administering the cell activator according to claim 27 to a mammal.

40 (New). A method of accelerating IL-10 production which comprises administering the cell activator according to claim 28 to a mammal.

41 (New). A method of activating NK cell which comprises administering the cell activator according to claim 27 to a mammal.

42 (New). A method of activating NK cell which comprises administering the cell activator according to claim 28 to a mammal.

43 (New). A method for treatment or prophylaxis of tumor comprises administering the cell activator according to claim 27 to a mammal.

44 (New). A method for treatment or prophylaxis of tumor comprises administering the cell activator according to claim 28 to a mammal.

45 (New). A method for treatment or prophylaxis of allergy comprises administering the cell activator according to claim 27 to a mammal.

46 (New). A method for treatment or prophylaxis of allergy comprises administering the cell activator according to claim 28 to a mammal.

47 (New). A method of enhancing resistance to infection which comprises administering the cell activator according to claim 27 to a mammal.

48 (New). A method of enhancing resistance to infection which comprises administering the cell activator according to claim 28 to a mammal.

49 (New). A method of inhibiting viral activity which comprises administering the cell according to claim 27 to a mammal.

50 (New). A method of inhibiting viral activity which comprises administering the cell activator according to claim 28 to a mammal.

51 (New). A method of accelerating IL-6 production which comprises administering the cell activator according to claim 27 to a mammal.

52 (New). A method of accelerating IL-6 production which comprises administering the cell activator according to claim 28 to a mammal.

53 (New). A method of accelerating NO production which comprises administering the cell activator according to claim 27 to a mammal.



In re of: 10/553,695

54 (New). A method of accelerating NO production which comprises administering the cell activator according to claim 28 to a mammal.